Elderly-Onset IBD: Epidemiology, Outcomes, Surgery, and Biologics in Veszprem Cohort

Overview

This population-based study analyzed 946 Crohn’s disease (CD) and 1370 ulcerative colitis (UC) patients from Veszprem County, focusing on elderly-onset (EO) IBD diagnosed at ≥60 years. EO CD patients had significantly higher early surgery rates and lower biologic exposure compared to adult-onset (AO), while EO UC patients showed similar biologic use and surgery rates to AO. Disease progression was lower in EO IBD for both CD and UC.

Background

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic inflammatory disorders requiring complex management. The elderly-onset subgroup, defined as diagnosis at age 60 or older, is increasing due to aging populations and rising IBD incidence. EO IBD may differ in clinical presentation, disease course, and treatment response compared to younger patients. However, prospective population-based data on EO IBD long-term outcomes remain limited. The Veszprem IBD cohort provides over 40 years of follow-up data to address these gaps.

Data Highlights

Key Findings

• EO IBD constituted 6.1% of CD and 13.4% of UC patients in the Veszprem cohort.
• EO CD patients had significantly lower exposure to biologic therapies compared to AO CD patients (p=0.003).
• Biologic therapy exposure in EO UC patients was comparable to AO UC patients (p=0.770).
• Early surgery rates within one year of diagnosis were significantly higher in EO CD patients (27.6%) than AO CD patients (15.6%, p<0.001).
• Overall resective surgery rates in CD and colectomy rates in UC did not differ significantly between EO and AO groups.
• Disease phenotype progression was significantly lower in EO CD and EO UC compared to their AO counterparts (p=0.015 and p=0.022, respectively).

Clinical Implications

Clinicians should recognize that elderly-onset IBD patients, particularly those with Crohn’s disease, may require earlier surgical intervention despite lower biologic therapy use. The similar biologic exposure in EO UC suggests that treatment strategies can be aligned with adult-onset protocols. Lower disease progression in EO IBD may influence monitoring intensity and therapeutic decisions. Awareness of these differences can optimize management and resource allocation in aging IBD populations.

Conclusion

Elderly-onset IBD represents a growing subset with distinct clinical features, including higher early surgery rates in CD and comparable biologic use in UC. Long-term outcomes and surgery rates are broadly similar to adult-onset disease, underscoring the need for tailored management strategies in this population.

References

1. ECCO Consensus 2016 -- Definition of Elderly-Onset IBD
2. Veszprem IBD Cohort Publications -- Longitudinal Population-Based Data
3. French Population-Based EO IBD Study -- Incidence and Outcomes
4. Dutch IBDSL Cohort -- Increasing EO IBD Incidence